# A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031

> **NCT00814736** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 22 (actual)

## Conditions studied

- Prostatic Hyperplasia
- Urinary Bladder, Overactive
- Erectile Dysfunction

## Interventions

- **DRUG:** UK369,003
- **DRUG:** sildenafil
- **DRUG:** sildenafil matching placebo

## Key facts

- **NCT ID:** NCT00814736
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2008-12-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00814736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00814736, "A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00814736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*